DuoLipo-TNP DuoLipo-TNP: Dual-Responsive Liposome Platform for Selective Delivery of Triphosphate Nucleotide Prodrugs in Triple-Negative Breast Cancer
- Coordinator
- Cardiff University, United Kingdom
- Runs
- 30 April 2027 to 29 April 2029
- Status
- Running
- EU funding
- €260k
- Total cost
- —
- Partners
- 2 organisations in 2 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101281416
What the project is doing
In the project's own words, from its summary on CORDIS.
Breast cancer is the most frequently diagnosed cancer in women worldwide and a leading cause of cancer mortality in Europe, with triple-negative breast cancer (TNBC) representing the most aggressive and therapy-resistant subtype. Driven by tumor heterogeneity, poor vascularization, and a hostile microenvironment, TNBC urgently requires new therapeutic strategies, an unmet clinical need directly aligned with the EU Mission on Cancer.
DuoLipo-TNP seeks to address these challenges by developing dual-responsive liposomal nanocarriers for the selective delivery of γ-masked triphosphate nucleotide prodrugs (TNPs). The platform combines tumor-penetrating iRGD peptides for αvβ3/αvβ5 integrin-mediated vascular targeting with lipid components responsive to hypoxia and acidic pH, two hallmark features of TNBC. This dual-triggered strategy enables site-specific release of active antimetabolites, bypasses kinase-dependent activation, and minimizes systemic toxicity.
The project applies a multidisciplinary approach spanning prodrug synthesis, advanced liposomal formulation and characterization, and comprehensive pharmacological validation in 2D and 3D TNBC models, including patient-derived spheroids. Ultimately, DuoLipo-TNP aims to establish a platform for intratumoral delivery of nucleotide analogues, advancing precision nanomedicine and contributing to the EU Mission on Cancer by improving outcomes in drug-resistant solid tumors.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Cardiff University | Cardiff | United Kingdom | Coordinator |
| Fundacao Gimm - Gulbenkian Institute for Molecular Medicine | Lisboa | Portugal | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI